

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 15270J-004740US

Assistant Commissioner for Patents
Attn: Box Missing Parts
Washington, D.C. 20231



4-11-01
ST

On December 13, 2000

TOWNSEND and TOWNSEND and CREW LLP

Paula Faulk Hurley

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

RECEIVED

JAN 02 2001

COMMUNICATION UNDER ~~TECH CENTER 1600, 2000~~

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed September 29, 2000, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

✓ On page 11, line 25, insert --(SEQ ID NO:1)-- after "-Ala-OH".

✓ On page 50, line 11, replace "NH₂-DAEFRHDSGYEVC-COOH" with --NH₂-DAEFRHDSGYEVC-COOH (SEQ ID NO:2)--.

✓ On page 50, line 12, replace "NH₂-DAEFRHDSGYEVC-COOH" with --NH₂-DAEFRHDSGYEVC-COOH (SEQ ID NO:3)--.